The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Newly-launched obesity company Kailera Therapeutics has announced the appointment of Jamie Coleman as chief commercial ...

“If you have commercial drug insurance with coverage for Zepbound, you may be eligible to pay as low as $25 for a one- or three-month supply of Zepbound,” Eli Lilly says. “One month is ...

Miracle drug innovations — such as those that sparked the meteoric rise of Wegovy and Zepbound — could come every couple of ...

Global commercial executive with expertise across product lifecycle and therapeutic areas leading transformative brands, ...

Zepbound is the newest GLP-1 medication to be approved by the Food and Drug Administration (FDA) for weight loss. It’s available only by prescription for people with a body mass index (BMI) of ...

Lilly Investors have listed Zepbound for $1,086.37 per fill. But the actual costs will vary depending on each patient's insurance coverage of prescription drugs. Those who have commercial drug ...

Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in sales could portend weaker long-term potential for this market. Lilly is positioned to remain the ...

Miracle drug innovations — such as those that sparked the meteoric rise of Wegovy and Zepbound — could come every couple of years thanks to new technologies, former U.S. Treasury Secretary ...